Skip to main content
Erschienen in: Journal of Neurology 1/2013

01.01.2013 | Original Communication

Estimation of Parkinson’s disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach

verfasst von: O. Chillag-Talmor, N. Giladi, S. Linn, T. Gurevich, B. El-Ad, B. Silverman, N. Friedman, C. Peretz

Erschienen in: Journal of Neurology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this work was to estimate in an incident cohort of pharmacy-based PD patients the survival of men and women accounting for age at treatment initiation and to compare their gender-specific survival with that of the general Israeli population. A population-based cohort of 4,848 incident pharmacy-based PD cases with definite/probable/possible certainty was previously identified using a drug-tracer approach for 1999–2008. Survival analysis was performed for two time scales: survival after treatment initiation (disease duration), and life-time survival (life expectancy). Kaplan–Meier curves and Cox regressions were used to compare survival across gender. Gender-specific SMRs were calculated from national rates and were compared using Poisson regression. During the follow-up from first purchase of any anti-parkinsonian drug (mean 4.0 ± 2.6 years, range 2 months–10 years), 1,266 (26 %) of the cases died. Younger age at first anti-parkinsonian drug purchase and female gender were associated with increased survival after treatment initiation (HR = 1.089, 95 % CI 1.080–1.098 for 1-year age increase; HR = 0.716, 95 % CI 0.640–0.800, females vs. males). Life-time survival increased with older age at first anti-parkinsonian drug purchase and female gender (HR = 0.759, 95 % CI 0.746–0.771 for 1-year age increase; HR = 0.694, 95 % CI 0.621–0.776, females vs. males). Sensitivity analysis on a sub-cohort of definite cases (n = 2501) yielded similar results. In comparison to the general Israeli population, mortality among pharmacy-based PD patients was significantly increased (SMRmen = 1.69, 95 % CI 1.57–1.81, SMRwomen = 1.49, 95 % CI 1.37–1.62), differently between genders (p < 0.01). Female gender was associated with longer, perhaps more benign disease course, and longer life expectancy. Earlier age at anti-parkinsonian drug initiation increased disease duration, but was associated with shorter life expectancy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ishihara LS, Cheesbrough A, Brayne C, Schrag A (2007) Estimated life expectancy of Parkinson’s patients compared with the UK population. J Neurol Neurosurg Psychiatry 78:1304–1309PubMedCrossRef Ishihara LS, Cheesbrough A, Brayne C, Schrag A (2007) Estimated life expectancy of Parkinson’s patients compared with the UK population. J Neurol Neurosurg Psychiatry 78:1304–1309PubMedCrossRef
2.
Zurück zum Zitat Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV (2006) Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 21:1221–1225PubMedCrossRef Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV (2006) Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 21:1221–1225PubMedCrossRef
3.
Zurück zum Zitat Chillag-Talmor O, Giladi N, Linn S et al (2011) Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson’s disease in a large Israeli population. J Parkinson’s Dis 1:35–47 Chillag-Talmor O, Giladi N, Linn S et al (2011) Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson’s disease in a large Israeli population. J Parkinson’s Dis 1:35–47
4.
Zurück zum Zitat Israel Central Bureau of Statistics (2010). Complete life tables of Israel, 2004–2008. Jerusalem Israel Central Bureau of Statistics (2010). Complete life tables of Israel, 2004–2008. Jerusalem
5.
Zurück zum Zitat Taeger D, Sun Y, Keil U, Straif K (2000) A stand-alone windows applications for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies. Epidemiology 11:607–608PubMedCrossRef Taeger D, Sun Y, Keil U, Straif K (2000) A stand-alone windows applications for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies. Epidemiology 11:607–608PubMedCrossRef
6.
Zurück zum Zitat Elbaz A, Bower JH, Peterson BJ et al (2003) Survival study of Parkinson disease in Olmsted County Minnesota. Arch Neurol 60:91–96PubMedCrossRef Elbaz A, Bower JH, Peterson BJ et al (2003) Survival study of Parkinson disease in Olmsted County Minnesota. Arch Neurol 60:91–96PubMedCrossRef
7.
Zurück zum Zitat Louis ED, Bennett DA (2007) Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 22:1681–1688PubMedCrossRef Louis ED, Bennett DA (2007) Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 22:1681–1688PubMedCrossRef
8.
Zurück zum Zitat Forsaa EB, Larsen JP, Wentzel-Larsen T et al (2010) What predicts mortality in Parkinson’s disease? A prospective population-based long-term study. Neurology 75:1270–1276PubMedCrossRef Forsaa EB, Larsen JP, Wentzel-Larsen T et al (2010) What predicts mortality in Parkinson’s disease? A prospective population-based long-term study. Neurology 75:1270–1276PubMedCrossRef
9.
Zurück zum Zitat Shulman LM, Bhat V (2006) Gender disparities in Parkinson’s disease. Expert Rev Neurother 6:407–416PubMedCrossRef Shulman LM, Bhat V (2006) Gender disparities in Parkinson’s disease. Expert Rev Neurother 6:407–416PubMedCrossRef
10.
Zurück zum Zitat Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2006) Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord 21:1002–1007PubMedCrossRef Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2006) Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord 21:1002–1007PubMedCrossRef
11.
Zurück zum Zitat Guttman M, Slaughter PM, Theriault ME, DeBoer DP (2001) Naylor CD Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 57(12):2278–2282PubMedCrossRef Guttman M, Slaughter PM, Theriault ME, DeBoer DP (2001) Naylor CD Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 57(12):2278–2282PubMedCrossRef
Metadaten
Titel
Estimation of Parkinson’s disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach
verfasst von
O. Chillag-Talmor
N. Giladi
S. Linn
T. Gurevich
B. El-Ad
B. Silverman
N. Friedman
C. Peretz
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 1/2013
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6584-5

Weitere Artikel der Ausgabe 1/2013

Journal of Neurology 1/2013 Zur Ausgabe

Medical Progress in the Journal of Neurology

Parkinson's disease related pain: a review of recent findings

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.